Literature DB >> 15228442

Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC.

M L Prasad1, Y Huang, N S Pellegata, A de la Chapelle, R T Kloos.   

Abstract

AIMS: Focal papillary thyroid carcinoma (PTC)-like nuclear alterations have been documented in Hashimoto's thyroiditis; however, the molecular association between PTC and Hashimoto's thyroiditis is poorly understood. The aim of this study was to determine whether molecular expression patterns of PTC are present in association with PTC-like nuclear alterations in Hashimoto's thyroiditis. METHODS AND
RESULTS: The expression of four genes known to be up-regulated in PTC [LGALS3 (galectin3), CITED1, KRT19 (cytokeratin 19) and FN1 (fibronectin-1)] and the human mesothelial cell protein identified by monoclonal antibody HBME1 was evaluated. Immunohistochemistry was performed on 23 cases of Hashimoto's thyroiditis with focal or diffuse Hürthle cell change and PTC-like nuclear alterations, 37 PTC and 18 normal thyroids. Focal expression of galectin3 (GAL3), CITED1, cytokeratin 19 (CK19), HBME1 and fibronectin-1 (FN1) was seen in 87%, 65%, 43%, 26% and 17% of Hashimoto's thyroiditis, respectively, only in thyrocytes showing PTC-like nuclear alterations. In contrast, diffuse expression of GAL3, CITED1, CK19, HBME1 and FN1 was seen in 100%, 95%, 70%, 87% and 89% of PTC, respectively. Normal thyroid tissues did not express any of these proteins. Following immunohistochemistry, four Hashimoto's thyroiditis cases were found to contain foci of PTC. These foci were highlighted by the diffuse and strong expression of PTC-associated proteins, which prompted additional retrospective scrutiny of the haematoxylin and eosin-stained sections leading to appreciation of complete PTC-type nuclear atypia.
CONCLUSIONS: Focal PTC-like immunophenotypic changes in Hashimoto's thyroiditis suggest the possibility of early, focal premalignant transformation in some cases of Hashimoto's thyroiditis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15228442     DOI: 10.1111/j.1365-2559.2004.01876.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  21 in total

1.  Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.

Authors:  Heng Ma; Jin Yan; Chao Zhang; Shenghui Qin; Lingzhi Qin; Liwei Liu; Xi Wang; Naping Li
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

Review 2.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

3.  Ectopic Cervical Thyroid Tissue Affected by Fibrosing Hashimoto's Thyroiditis Mimicking Multifocal Metastatic Papillary Thyroid Carcinoma-A Hard Lesson Learnt from an Unusual Case.

Authors:  Hui Min Tan; Min En Nga; Fredrik Petersson
Journal:  Head Neck Pathol       Date:  2020-05-25

4.  iTRAQ-coupled 2D LC/MS-MS analysis of CXCR7-transfected papillary thyroid carcinoma cells: A new insight into CXCR7 regulation of papillary thyroid carcinoma progression and identification of potential biomarkers.

Authors:  Hengwei Zhang; Lei Yang; Zhangyi Liu; Chenxi Liu; Xuyong Teng; Lei Zhang; Bo Yin; Zhen Liu
Journal:  Oncol Lett       Date:  2017-07-15       Impact factor: 2.967

5.  Increased risk of papillary thyroid cancer in celiac disease.

Authors:  Laura Kent; Russell McBride; Robert McConnell; Alfred I Neugut; Govind Bhagat; Peter H R Green
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

6.  Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.

Authors:  Figen Barut; Nilufer Onak Kandemir; Sibel Bektas; Burak Bahadir; Sevinc Keser; Sukru Oguz Ozdamar
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

7.  Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.

Authors:  Peter M Sadow; Michael C Heinrich; Christopher L Corless; Jonathan A Fletcher; Vânia Nosé
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

8.  Follicular epithelial dysplasia of the thyroid: morphological and immunohistochemical characterization of a putative preneoplastic lesion to papillary thyroid carcinoma in chronic lymphocytic thyroiditis.

Authors:  Michael Herman Chui; Clarissa A Cassol; Sylvia L Asa; Ozgur Mete
Journal:  Virchows Arch       Date:  2013-03-27       Impact factor: 4.064

9.  Common single nucleotide polymorphisms in genes related to immune function and risk of papillary thyroid cancer.

Authors:  Alina V Brenner; Gila Neta; Erich M Sturgis; Ruth M Pfeiffer; Amy Hutchinson; Meredith Yeager; Li Xu; Cindy Zhou; William Wheeler; Margaret A Tucker; Stephen J Chanock; Alice J Sigurdson
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

10.  The clinical features of papillary thyroid cancer in Hashimoto's thyroiditis patients from an area with a high prevalence of Hashimoto's disease.

Authors:  Ling Zhang; Hui Li; Qing-hai Ji; Yong-xue Zhu; Zhuo-ying Wang; Yu Wang; Cai-ping Huang; Qiang Shen; Duan-shu Li; Yi Wu
Journal:  BMC Cancer       Date:  2012-12-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.